SCHEMBL1979092

SCHEMBL1979092

CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O

nearest known ligand 0.96

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.96
RCOR1 Q9UKL0 3/20 0.85
LDHB P07195 4/20 0.42
TERF2IP Q9NYB0 2/20 0.38
ESR1 P03372 2/20 0.37
ESR2 Q92731 1/20 0.37
KEAP1 Q14145 1/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
NPY4R P50391 1/20 0.36
NPY5R Q15761 1/20 0.36
JAK1 P23458 1/20 0.35
CTNNB1 P35222 1/20 0.35
STAT1 P42224 1/20 0.35
F11 P03951 2/20 0.35
EGFR P00533 1/20 0.34
LCK P06239 1/20 0.34
TERF2 Q15554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24437319 1.00 KDM1A (0.96) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL16549279 1.00 KDM1A (0.96) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL29360957 1.00 KDM1A (0.96) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL29380446 1.00 KDM1A (0.96) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL691747 1.00 KDM1A (0.96) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL31066574 0.98 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL49226 0.98 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL18902532 0.98 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL21476977 0.98 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPESR1
SCHEMBL21474097 0.97 KDM1A (0.99) KDM1ARCOR1LDHBTERF2IPESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117241773-A Polymer medicine bottle with standard external dimensions and reduced internal volume SIO2医疗产品有限公司 2023-12-15 CN claimed
CN-102228161-A Compound feed for reducing nitrogen and phosphorus excretions of growing pigs ZHENGZHOU COLLEGE ANIMAL HUSBANDRY ENG 2011-11-02 CN claimed
CN-115666716-B Lighting device for inducing biological effects Nuo bio Co.,Ltd. (US) 2026-05-26 CN disclosed
US-20260124224-A1 USE OF COMBINED COMPOSITION IN PREPARING DRUG FOR RESISTING FUNGAL AND BACTERIAL INFECTIONS NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (CN) 2026-05-07 US disclosed
WO-2026096690-A1 COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATION AND COGNITIVE DECLINE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-07 WO disclosed
WO-2026095932-A1 COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATION AND COGNITIVE DECLINE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-07 WO disclosed
EP-4731266-A1 NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES The Regents of the University of Michigan (US) 2026-04-29 EP disclosed
US-20260097045-A1 ANTIMICROBIAL COMBINATIONS HELPERBY THERAPEUTICS LIMITED (GB) 2026-04-09 US disclosed
US-12594319-B2 Pharmaceutical development HELPERBY THERAPEUTICS LIMITED (GB) 2026-04-07 US disclosed
US-12563857-B2 Photovoltaic device including a p-n junction and method of manufacturing FIRST SOLAR, INC. (US) 2026-02-24 US disclosed
US-20260042800-A1 ANTIMICROBIAL PEPTIDOMIMETICS BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) 2026-02-12 US disclosed
US-20160002296-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS (DK) 2016-01-07 US disclosed
EP-2943503-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE Xellia Pharmaceuticals ApS (DK) 2015-11-18 EP disclosed
CN-104918951-A POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS 2015-09-16 CN disclosed
WO-2014108469-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE XELLIA PHARMACEUTICALS APS (DK) 2014-07-17 WO disclosed
CN-103229746-A Safe pig breeding method SHAANXI SHIYANG GROUP FEED DEV CO LTD 2013-08-07 CN disclosed
CN-102228161-A Compound feed for reducing nitrogen and phosphorus excretions of growing pigs ZHENGZHOU COLLEGE ANIMAL HUSBANDRY ENG 2011-11-02 CN disclosed
US-7960164-B2 Selective growth medium for Listeria spp PARADIGM DIAGNOSTICS, INC. (US) 2011-06-14 US disclosed
US-20080020445-A1 Selective Growth Medium for Listeria Spp PARADIGM DIAGNOSTICS, INC. 2008-01-24 US disclosed
WO-2005079276-A2 SELECTIVE GROWTH MEDIUM FOR LISTERIA SPP PARADIGM DIAGNOSTICS, INC. (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124224-A1 USE OF COMBINED COMPOSITION IN PREPARING DRUG FOR RESISTING FUNGAL AND BACTERIAL INFECTIONS ERG28, MYD88, SLC11A2 KDM1A 3513/4885RCOR1 3373/4885LDHB 3796/4885
US-12563857-B2 Photovoltaic device including a p-n junction and method of manufacturing DSP, SLC6A12, SLC6A6 KDM1A 3884/4885RCOR1 4060/4885LDHB 4295/4885
US-20160002296-A1 POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE C5, SGMS1, SGMS2 KDM1A 2574/4885RCOR1 2534/4885LDHB 3744/4885
US-20260042800-A1 ANTIMICROBIAL PEPTIDOMIMETICS CUTA, NGLY1, P4HB KDM1A 3524/4885RCOR1 3762/4885LDHB 991/4885
US-12594319-B2 Pharmaceutical development TMSB10, TMEM165, PCTP KDM1A 3641/4885RCOR1 4874/4885LDHB 1914/4885
US-20260097045-A1 ANTIMICROBIAL COMBINATIONS ZYX, TREH, PRF1 KDM1A 3365/4885RCOR1 4649/4885LDHB 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.